These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 24141629)

  • 1. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
    Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
    Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.
    Ginestier C; Monville F; Wicinski J; Cabaud O; Cervera N; Josselin E; Finetti P; Guille A; Larderet G; Viens P; Sebti S; Bertucci F; Birnbaum D; Charafe-Jauffret E
    Stem Cells; 2012 Jul; 30(7):1327-37. PubMed ID: 22605458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
    Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
    Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.
    Gressette M; Vérillaud B; Jimenez-Pailhès AS; Lelièvre H; Lo KW; Ferrand FR; Gattolliat CH; Jacquet-Bescond A; Kraus-Berthier L; Depil S; Busson P
    PLoS One; 2014; 9(3):e91325. PubMed ID: 24618637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.
    Charafe-Jauffret E; Ginestier C; Bertucci F; Cabaud O; Wicinski J; Finetti P; Josselin E; Adelaide J; Nguyen TT; Monville F; Jacquemier J; Thomassin-Piana J; Pinna G; Jalaguier A; Lambaudie E; Houvenaeghel G; Xerri L; Harel-Bellan A; Chaffanet M; Viens P; Birnbaum D
    Cancer Res; 2013 Dec; 73(24):7290-300. PubMed ID: 24142344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
    Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Library Screen Identifies Abexinostat as Novel Regulator of Adipocytic and Osteoblastic Differentiation of Human Skeletal (Mesenchymal) Stem Cells.
    Ali D; Hamam R; Alfayez M; Kassem M; Aldahmash A; Alajez NM
    Stem Cells Transl Med; 2016 Aug; 5(8):1036-47. PubMed ID: 27194745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
    Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
    Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PGE
    Lin MC; Chen SY; He PL; Herschman H; Li HJ
    Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.
    Marcato P; Dean CA; Pan D; Araslanova R; Gillis M; Joshi M; Helyer L; Pan L; Leidal A; Gujar S; Giacomantonio CA; Lee PW
    Stem Cells; 2011 Jan; 29(1):32-45. PubMed ID: 21280157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
    Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO
    Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
    Li J; Zhang T; Yang F; He Y; Dai F; Gao D; Chen Y; Liu M; Yi Z
    Br J Pharmacol; 2015 Aug; 172(15):3817-30. PubMed ID: 25884486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
    Chikamatsu K; Ishii H; Murata T; Sakakura K; Shino M; Toyoda M; Takahashi K; Masuyama K
    Cancer Sci; 2013 Nov; 104(11):1468-75. PubMed ID: 23992541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.